Monitor 14-Drug Class Profile (LabCorp MedWatch®)

CPT: 80307
Print Share

Test Details


  • Immunoassay 14

Test Includes

Amphetamine; barbiturates; benzodiazepines; buprenorphine; cocaine (and metabolite); creatinine; fentanyl; meperidine; methadone; opiate; oxycodone/oxymorphone; pH; phencyclidine (PCP); propoxyphene; specific gravity; tetrahydrocannabinol (THC); tramadol. Note: Contains expanded benzodiazepine confirmation upon reflex of positive screen. Positive expanded benzodiazepine screen includes alpha-hydroxy-alprazolam, alpha-hydroxy-midazolam, alpha-hydroxy-triazolam, 7-aminoclonazepam, hydroxy-ethyl-flurazepam, lorazepam, nordiazepam, oxazepam, and temazepam. Opiate confirmation of positive screen includes hydrocodone, hydromorphone, codeine, and morphine.


Detect and confirm presence of prescribed and illicit drugs


Initial testing by immunoassay (IA); confirmation of positive by mass spectrometry (MS)

Specimen Requirements




30 mL


Plastic urine container

Storage Instructions

Maintain specimen at room temperature. If arrival at laboratory extends beyond seven days, refrigerate.

Clinical Information

Special Instructions

This profile is designed for pain management. It is not intended for workplace testing and does not comply with state regulatory workplace testing programs.

For Providers

Please login to order a test.


© 2018  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at